Transcription
CLICK TO VIEWINDUSTRY MARKET RESEARCH FOR BUSINESS LEADERS, STRATEGISTS, DECISION MAKERSTable of Contents 2List of Tables & Charts 3Study Overview 4Sample Text, Table& Chart 5Sample Profile, Table &Forecast 6Order Form 7About Freedonia, CustomResearch, Related Studies,Corporate Use License 8Pet Health:Products & ServicesUS Industry Study with Forecasts for 2014 & 2019Study #2660 August 2010 4800 285 pagesThe Freedonia Group767 Beta Drivewww.freedoniagroup.comCleveland, OH 44143-2326 USAToll Free US Tel: 800.927.5900 or 1 440.684.9600Fax: 1 440.646.0484E-mail: info@freedoniagroup.com
Study #2660August 2010 4800285 PagesPet Health: Products & ServicesUS Industry Study with Forecasts for 2014 & 2019Table of ContentsExecutive SummaryMarket EnvironmenTGeneral. 4Macroeconomic Outlook. 4Consumer Income & Spending Trends. 8Demographic Trends. 11Population. 11Household Formation. 13Pet Demographic Trends. 16Cats. 18Dogs. 20Other Pets. 22Pet Health Service Provider Overview. 23Veterinary Practices & Employment 24Non-Veterinary Pet Care. 26Pet & Pet Supply Stores. 27Pet Insurance. 27Medical Conditions. 28Pet Health Spending Overview. 30Nontraditional Health Care. 32Regulatory & Environmental Issues. 33Center for Veterinary Medicine. 34Animal & Plant HealthInspection Service. 36Environmental Protection Agency. 38Other Regulations. 39World Pet Health Care Market. 39SERVICESGeneral. 42Veterinary Care. 44Surgery. 45Growth Removal. 47Orthopedic. 48Gastrointestinal. 48Neutering/Spaying. 48Cosmetic Procedures. 49Other Surgical Procedures. 52Non-Surgical Procedures. 54Non-Veterinary Pet Care. 56Pet Insurance. 58Available Plans. 61Market Share. 63PRODUCTSINDUSTRY STRUCTUREGeneral. 70Pharmaceuticals. 72Systemic Agents. 75Hormones & Insulin. 77Pain Control. 79Anti-Inflammatory Agents. 81Gastrointestinal Systemic Agents 84Respiratory Systemic Agents. 85Cardiovascular Systemic Agents. 85Other Systemic Agents. 87Antibiotics. 90Other Pharmaceuticals. 92Anesthetic Agents. 93Euthanasia Agents. 95All Other Pharmaceuticals. 96Parasiticides. 99Flea & Tick.101Heartworm.104Other Parasiticides.106Prescription Food.108Dietary Supplements.110Vaccines.114Diagnostics.117Other Pet Health Products.119General.167Market Share.170Industry Restructuring.175Competitive Strategies.179Cooperative Agreements.181Marketing.185Distribution Channels.186CONDITIONSGeneral.123Skin Conditions.125Heart Conditions.129Gastrointestinal Conditions.132Renal Conditions.135Arthritis.138Diabetes.141Other Conditions.144Respiratory Conditions.145Cancer.146All Other her.162Click here to purchase onlinePage Company ProfilesAbbott Laboratories.189ADER Enterprises.191Bayer AG.192Boehringer Ingelheim.195Central Garden & Pet.198Church & Dwight.202Colgate-Palmolive Company.203Embrace Pet Insurance.205Hartville Group.207Heska Corporation.209IDEXX Laboratories.213Mars Incorporated.217Merck & Company.219Nestle SA.224Novartis AG.227Nutri-Vet LLC.229PBI/Gordon.232Pet DRx Corporation.235PetAg Incorporated.236Pethealth Incorporated.238Pfizer Incorporated.240Procter & Gamble.248Sanofi-Aventis.250Sergeant’s Pet Care Products.253Spectrum Brands.257Sumitomo Corporation.262VCA Antech.266Veterinary Pet Insurance.268Virbac SA.270Other CompaniesMentioned in Study.274Order now, click here!
Study #2660August 2010 4800285 PagesPet Health: Products & ServicesUS Industry Study with Forecasts for 2014 & 2019List of TablesExecutive Summary1 Summary Table. 3Market EnvironmenT1 Macroeconomic Indicators. 82 Personal ConsumptionExpenditures. 103 Population. 134 Households & Pet Ownership. 165 Pet Population. 186 Pet Health Service Providers. 247 Selected Pet Medical Conditions. 308 Pet Health Retail Sales& Services Revenues. 32SERVICES1 Pet Health ServiceRevenues by Type. 432 Veterinary Care ServiceRevenues by Type. 453 Surgery Revenues by Type. 474 Non-Surgical Revenues by Type. 565 Non-Veterinary Pet Care Revenues 586 Pet Insurance Revenues. 61PRODUCTS1 Pet Health ProductDemand by Type. 712 Pharmaceuticals Demandby Type & Animal. 753 Systemic Agents Demandby Type & Animal. 774 Antibiotics Demandby Type & Animal. 925 Other Pharmaceuticals Demandby Type & Animal. 936 Parasiticides Demandby Type & Animal.1017 Flea & Tick Treatment Demandby Type & Animal.1048 Heartworm Treatment Demandby Type & Animal.1069 Other ParasiticidesDemand by Animal.10810 Prescription Pet FoodDemand by Animal.11011 Dietary Supplement Demandby Type & Animal.11412 Vaccines Demand by Animal.11713 Diagnostics Demand by Animal.11914 Other Pet Health Product Demandby Product & Animal.122CONDITIONS1 Pet Health ProductDemand by Condition.1242 Skin Conditions: Pet HealthProduct Demandby Type & Animal.1293 Heart Conditions: Pet HealthProduct Demandby Type & Animal.1324 Gastrointestinal Conditions:Pet Health Product Demandby Type & Animal.1355 Renal Conditions: Pet HealthProduct Demandby Type & Animal.1386 Arthritis: Pet Health ProductDemand by Type & Animal.1417 Diabetes: Pet Health ProductDemand by Type & Animal.1448 Other Conditions: Pet HealthProduct Demand by Type,Condition & Animal.145ANIMALS1 Pet Health ProductDemand by Animal.1532 Dog Health ProductDemand by Type.158Click here to purchase onlinePage 3 Cat Health ProductDemand by Type.1624 Other Pet Health ProductDemand by Type.166INDUSTRY STRUCTURE1 Pet Health Product Salesby Company, 2009.1682 Selected Acquisitions& Divestitures.1783 Selected CooperativeAgreements.183List of ChartsMarket EnvironmenT1 World Pet Health Product& Service Demand, 2009. 41SERVICES1 Pet Insurance Market Shareby Company, 2009. 64PRODUCTS1 Pet Health ProductDemand by Type, 2009. 72CONDITIONS1 Pet Health Product Demandby Condition, 2009.125ANIMALS1 Pet Health Product Demandby Animal, 2009.154INDUSTRY STRUCTURE1 Pet Health Product Market Shareby Company, 2009.171Order now, click here!
Study #2660August 2010 4800285 PagesPet Health: Products & ServicesUS Industry Study with Forecasts for 2014 & 2019Pets are often considered to be members of the family rather than merely companion animals, and spending on their health care is thus perceived as a necessary expense.US spending to rise 6.5%annually through 2014Total US spending on pet health products and services is expected to advance 6.5 percent annually to 33.1billion in 2014. At that time, there will beover 200 million pets in the US and 62percent of households will own at leastone. Pets are often considered to bemembers of the family rather thanmerely companion animals, and spending on their health care is thus perceivedas a necessary expense. Also drivinggrowth will be a recovery from theeconomic recession that began inDecember 2007, as well as advances inveterinary technology (including humangrade medicine and procedures becoming adapted to pet-specific care).Pet insurance to befastest growing servicePet health services encompass veterinary care, non-veterinary care and petinsurance. Surgical and non-surgicalveterinary care will continue to seetechnology transfer from human medicine, such as in cosmetic surgery,dialysis and organ transplant procedures. Newly available services typicallycost significantly more than establishedprocedures, adding to revenue gains. Toimprove affordability, rising numbers ofowners will purchase insurance policiesfor their pets. Pet insurance will continueto see the fastest demand growth of allpet health products and services, risingnearly 17 percent per year through 2014.While penetration rates will remain low,Services63%( 24.2 billion)Retail Products37%both the percent of insured pets andoverall insurance revenues will doubleby 2014.Pharmaceuticals nowlargest product segmentIn 2009, pharmaceuticals overtookparasiticides to account for the largestshare of demand in the pet healthproduct market, with 34 percent of thetotal. Gains for pharmaceuticals will beabove the overall average through 2014,driven by new pet-specific formulationsto treat conditions such as obesity andmental disorders (e.g., separationanxiety). Faster gains will be held backby rising competition from naturalremedies and supplements. Until 2009,Click here to purchase onlinePage US Pet Health Spending, 2009parasiticides represented the largestsegment of pet health product demand.However, due to wide and establishedmarket penetration, gains have beenbelow-average for the last decade or so.Dietary supplements tobe fastest growing productFast increases will be seen in dietarysupplements, following trends in humanmarkets and benefiting from wideningretail availability. Tempering gains tosome extent will be the inclusion ofvitamin and other nutritional additives inpremium and prescription pet food.Other products include vaccines, diagnostics and miscellaneous items such asdisinfectants.Copyright 2010 The Freedonia Group, Inc.Order now, click here!
Study #2660August 2010 4800285 PagesPet Health: Products & ServicesUS Industry Study with Forecasts for 2014 & 2019Sample Text,Table & ChartTABLE IV-3SYSTEMIC AGENTS DEMAND BY TYPE & ANIMAL(million dollars)Item1999 2004 2009 2014 2019Pet Population (million) 168.5 182.3 193.6 206.5 219.0 systemic agents/pet 1.41 1.83 2.39 3.20 4.25productsSystemic Agents Demand 237 333 463 660 930By Type:Gastrointestinal Systemic Agents -- Demand for gastrointes Hormones & Insulin5586 127 191 290tinal systemic agents used to treat pets is forecast to increase 5.9 percentPain Control 466180 106 140per year to 52 million in 2014. Gastrointestinal systemic agentsincludeAnti-Inflammatories 41557398 135anti-bloat, anti-diarrheal and anti-ulcer treatments; appetite stimulants;Gastrointestinal2430395270laxatives; and vomiting controls and stimulants. Virtually all drugsusedRespiratory1115213045to treat gastrointestinal disorders in pets are pharmaceuticals approvedCardiovascular812182840for human use.Other5274 105 155 210By Animal:Diarrheal treatment agents include mucosal protectants and adsor Dog 149 208 288 407 565bents (including activated charcoal, bismuth subsalicylate and kaolin Cat83 118 165 238 340pectin formulations), motility-modifying agents (such as anticholinergicOther57101525drugs including atropine), antimicrobial therapy, NSAIDs, and antitoxins. Med-Pharmex’s KAO-PECTIN liquid formula and PBI/Gordon’s% systemic agents 29.6 31.6 33.0 34.6 35.8PET PECTILLIN are among available anti-diarrheal veterinary drugs.Pharmaceuticals Demand 801 1055 1402 1905 2600Anti-ulcer treatments are largely off-label human products, and include antacids and histamine-receptor antagonists. Antacids neutralize stomach acid and are based on aluminum, calcium or magnesium-- most often aluminum hydroxide, calcium carbonate and magnesiumoxide/hydroxide. Cimetidine, famotidine and rantidine are the mostoften employed histamine-receptor antagonists used to block gastric acidsecretion in pets to prevent ulcer formation. Appetite stimulants are usedto cure anorectic animals, and may include boldenone undecylenate,cyproheptadine, megestrol acetate and prednisone.sampletablesampletextAmong the drug therapies used as laxatives in pet treatment arebisacodyl; docusate calcium, docusate potassium and docusate sodium; and lactulose. Magnesium sulfate (Epsom salts) and magnesiumCHART VII-1hydroxide (milk of magnesia) also have laxative effects. Laxatives arecategorized as fecal softeners (surfactants), hydrophilic colloids, hyperPET HEALTH PRODUCT MARKET SHARE BY COMPANYosmotic cathartics, lubricant laxatives and stimulant cathartics. Vomit( 4.2 billion, 2009)ing stimulation and control therapies are classified as emetic drugs andantiemetic drugs, respectively. Emetic drugs typically are used in84Copyright 2010 The Freedonia Group, Inc.O th e rs5 1 .8 %Click here to purchase onlinePage samplechartM a rke tL e a d e rs4 8 .2 %16.8%P f iz er14.9%M erial7.2%B ayer5.5%N o v art is3.8%M erckOrder now, click here!
Study #2660August 2010 4800285 PagesPet Health: Products & ServicesUS Industry Study with Forecasts for 2014 & 2019Sample Profile,Table & ForecastTABLE V-1PET HEALTH PRODUCT DEMAND BY CONDITION(million dollars)Item1999 2004 2009 2014 2019Pet Population (million) 168.5 182.3 193.6 206.5 219.0 health product/pet 14.0 17.2 21.5 26.8 33.4Pet Health Product Demand 2355 3144 4170 5530 7310Skin 724 905 1123 1380 1690Heart 469 613 801 1030 1310Gastrointestinal 268 347 455 582 750Renal 158 211 275 375 510Arthritis 108 175 260 380 560Diabetes 113 163 231 328 465Other 515 730 1025 1455 2025sampletableCOMPANY PROFILESPetAg Incorporated255 Keyes AvenueHampshire, IL Annual Sales: 12 million (estimated)Employment: 65 (estimated)Key Products: supplements, other health aids and specialty treats forcats, dogs, birds, reptiles and small mammalsPetAg is a manufacturer of health and nutrition products for pets.The Company is privately held.The Company participates in the US pet health industry throughthe manufacture of a variety of health and nutrition products for cats,dogs, birds, reptiles and small mammals. Among these products aresupplements, other health aids and specialty treats. PetAg operatesa 60,000-square-foot plant in Hampshire, Illinois. This facility alsoincludes a quality control laboratory.PetAg produces a variety of dietary supplements for cats, including the following products: chewable taurine tablets; calcium phosphorus powder and tablet supplements; VISION AID gel, an oral supplement formulated with arginine, methionine, beta-carotene and carnitineto support vision development and ocular maintenance; CATSUREliquid supplements containing antioxidants, omega-3 and omega-6 fattyacids, vitamins and minerals to meet the nutritional needs of seniorcats; FORMULA V enteral care liquid supplements made with vitamins, minerals, fatty acids, fiber and other ingredients; MIRRA-COATliquid supplements designed to reduce shedding, scratching and flaky236Copyright 2010 The Freedonia Group, Inc.Click here to purchase onlinePage “Demand for products indicated for thetreatment of heart conditions in companion animals is expected to rise 5.2 percentper year to 1 billion in 2014. As morepets are diagnosed with heart conditions,partially due to rising obesity rates, salesof products intended to prevent and treatheart disease will continue to rise. Preventive products, principally parasiticides,will experience the largest growth inabsolute demand, representing a maturingmarket for preventives. Prescription foodand pharmaceuticals intended to maintainthe health of pets diagnosed with chronicheart conditions will see healthy gainsfrom a small base; .”--Section V, pg. 129-30Order now, click here!
Order InformationINDUSTRY MARKET RESEARCH FOR BUSINESSLEADERS, STRATEGISTS, DECISION MAKERSFive Convenient Ways to OrderONLINE: www.freedoniagroup.comMAIL: Print out and complete the orderform and send to The Freedonia Group(see address at the bottom of this form)PHONE: Call toll free, 800.927.5900(US) or 1 440.684.9600FAX: 1 440.646.0484 (US)EMAIL: info@freedoniagroup.comFree Handling & ShippingCredit Card OrdersOrders Outside of the USSave 15%There is NO charge for handling or UPS shippingin the US. Expect delivery in 3 to 5 business days.Outside the US, Freedonia provides free airmailservice. Express delivery is available at cost.Checks must be made payable in US funds,drawn against a US bank and mailed directly toThe Freedonia Group. For wire transfers pleasecontact our customer service department at info@freedoniagroup.com. Credit cards accepted.For convenience, Freedonia accepts American Express, MasterCard or Visa. Credit card purchasesmust include account number, expiration date andauthorized signature.If you order three (3) different titles at the sametime, you can receive a 15% discount. If yourorder is accompanied by a check or wire transfer,you may take a 5% cash discount (discounts donot apply to Corporate Use Licenses).Corporate Use LicenseNow every decision maker in your organization can act on the key intelligence found in allFreedonia studies. For an additional 2600, companies receive unlimited use of an electronicversion (PDF) of the study. Place it on your intranet, e-mail it to coworkers around the world,or print it as many times as you like,Order FormF-WEB.2660Pet Health: Products & Services. 4800Corporate Use License (add to study price) * 2600Additional Print Copies @ 600 each *NameTitleCompanyDivisionTotal (including selected option) Enclosed is my check (5% discount) drawn on a US bank and payable toThe Freedonia Group, Inc., in US funds (Ohio residents add 7.75% sales tax)StreetBill my companyCity/State/ZipAmerican ExpressMasterCardClick here to learn more aboutthe Corporate Use LicenseVisaMM(No PO Box please)YYCountryCredit Card #ExpirationPhoneFaxEmailSignature* Please check appropriate option and sign below to order an electronicversion of the study.Individual Use License AgreementThe above captioned study may be stored on the company’s intranet orshared directory, available to company employees. Copies of the study maybe made, but the undersigned represents that distribution of the study willbe limited to employees of the company.The undersigned hereby represents that the above captioned study will beused by only individual(s) who are employees of the company and thatthe study will not be loaded on a network for multiple users. In the eventthat usage of the study changes, the Company will promptly notify Freedonia of such change and will pay to Freedonia the appropriate fee based onFreedonia’s standard fee schedule then in effect. Note: Entire company corporate use license, add 2600; one additional user, add 600; two additionalusers, add 1200; three additional users, add 1800.SignatureSignatureCorporate Use License AgreementThe Freedonia Group, Inc. 767 Beta Drive Cleveland, OH 44143-2326 USA Web site: www.freedoniagroup.comTel US: 800.927.5900 or 1 440.684.9600 Fax: 1 440.646.0484 e-mail: info@freedoniagroup.comPage 7
INDUSTRY MARKET RESEARCH FOR BUSINESS LEADERS, STRATEGISTS, DECISION MAKERSOther StudiesVaccinesThis study analyzes the US human and veterinaryvaccine industry. It presents historical demand data(1999, 2004, 2009) and forecasts to 2014 and 2019by vaccine type (e.g., pediatric, hepatitis, biodefense,smallpox, anthrax, influenza, Encephalitis, rabies,SARS, meningococcal, BCG, livestock, companionanimal). The study also presents macro- and socioeconomic demand indicator data, details industrystructure, evaluates company market share andprofiles industry competitors.#2667. 08/2010. 4700Nanotechnology in Health CareUS demand for nanosized medical products willgrow 17.1% yearly though 2014. Cancer and centralnervous system disorders will be the fastest growingapplications. Nanomedicines will provide the best opportunities, while nanotech medical supplies and devices grow the fastest from a small base. This studyanalyzes the 34.2 billion US nanotechnology medical product industry, with forecasts for 2014 and 2019by product and application. It also evaluates companymarket share and profiles industry participants.#2622. 06/2010. 4800Implantable Medical DevicesUS demand for implantable medical devices willincrease 8.3% annually through 2014. Gains will bedriven by the development of next generation devicesbased on new technologies and improved materials.Spinal implants, cardiac stents and orthobiologics willbe among the fastest growing product categories.This study analyzes the 33 billion US implantablemedical device industry, with forecasts for 2014 and2019 by procedure, material and type. It also evaluates company market share and profiles 36 industrycompetitors.#2595. 04/2010. 4800World WoundManagement ProductsGlobal wound management product demand will rise4.6% yearly through 2013. Best growth prospectsinclude tissue sealants, foam and alginate wounddressings, growth factors, bioengineered tissuesubstitutes and anti-adhesion agents. China will bethe fastest growing market, while the US remainsthe largest. This study analyzes the global market forwound management products, with forecasts for 2013and 2018 by type, world region and for 13 countries.It also evaluates company market share and profilesindustry players.About The Freedonia GroupThe Freedonia Group, Inc., is a leading international industry market research company that provides its clients with information and analysis needed to make informedstrategic decisions for their businesses. Studies help clients identify business opportunities, develop strategies, make investment decisions and evaluate opportunitiesand threats. Freedonia research is designed to deliver unbiased views and reliableoutlooks to assist clients in making the right decisions. Freedonia capitalizes onthe resources of its proprietary in-house research team of experienced economists,professional analysts, industry researchers and editorial groups. Freedonia covers adiverse group of industries throughout the United States, the emerging China market, and other world markets. Industries analyzed by Freedonia include: Chemicals Plastics Life Sciences Packaging Building Materials Security& Electronics Industrial Components & Equipment Automotive & TransportationEquipment Household Goods Energy/Power EquipmentClick here to learn more about FreedoniaFreedonia Custom ResearchFreedonia Custom Research delivers the same high quality, thorough and unbiasedassessment of an industry or market as an industry study. Since the research initiative is based upon a company’s specific needs, companies harness Freedonia’sresearch capabilities and resources to answer unique questions. When you leveragethe results of a Freedonia Custom Research engagement, you are able to obtainimportant answers to specific questions and issues associated with: mergers andacquisitions, new product launches/development, geographic expansion, entry intonew markets, strategic business planning, and investment and funding decisions.Freedonia Custom Research is ideal for companies seeking to make a strategic difference in the status quo and focus on future business growth. Working side by sidewith clients, Freedonia’s team is able to define a research project that is customtailored to answer specific questions and provide the basis from which a companycan make informed business decisions.Click here to learn more about Custom Research#2578. 02/2010. 5800World Nutraceutical IngredientsGlobal nutraceutical ingredient demand will rise 6.2%yearly through 2013. China and India will be thefastest growing markets while the US remains thelargest. Best prospects include soy proteins; additives lutein and lycopene; vitamins A and E; mineralscalcium and magnesium; and extracts ginkgo bilobaand glucosamine. This study analyzes the 16 billionworld nutraceutical ingredient industry, with forecastsfor 2013 and 2018 by product, world region and for12 countries. It also details market share and profilesindustry players.#2565. 11/2009. 5800Page 8Click here for complete title listClick here to visit freedoniagroup.comThe Freedonia Group, Inc. 767 Beta Drive Cleveland, OH 44143-2326 USA Web site: www.freedoniagroup.comTel US: 800.927.5900 or 1 440.684.9600 Fax: 1 440.646.0484 e-mail: info@freedoniagroup.com
Cleveland, OH 44143-2326 USA Toll Free US Tel: 800.927.5900 or 1 440.684.9600 Fax: 1 440.646.0484 E-mail: info@freedoniagroup.com The Freedonia Group www.freedoniagroup.com Table of Contents 2 List of Tables & Charts 3 Study Overview 4 Sample Text, Table & Chart 5 Sample Profile, Table & Forecast 6 Order Form 7 About Freedonia, Custom
